DOCSLIB.ORG

Isotretinoin- Dose, Duration, Relapse: Rademaker

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Isotretinoin- Dose, Duration, Relapse: Rademaker bs_bs_banner Australasian Journal of Dermatology (2012) ••, ••–•• doi: 10.1111/j.1440-0960.2012.00947.x REVIEW ARTICLE Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Marius Rademaker Dermatology Department, Waikato Hospital, Hamilton, New Zealand ABSTRACT and extrinsic (photo) aging. Teratogenicity however, remains a very significant concern. With 30 years of clinical use, it is appropriate to review the use of isotretinoin. We now understand Key words: acne vulgaris, adverse effects, dose, that retinoids influence cellular growth, differentia- isotretinoin, relapse, retinoid. tion, morphogenesis and apoptosis, inhibit tumour promotion and malignant cell growth, exert immuno- modulatory actions and alter cellular cohesiveness. INTRODUCTION This has expanded the indications of isotretinoin from just acne and rosacea to a wide range of inflammatory Since achieving registration in the USA in 1982, isotretinoin and malignant skin disorders. While the standard has truly revolutionised the management of acne vulgaris,1 dose of 0.5 to 1 mg/kg per day for 4 months to a as well as finding a place in the treatment of a number of cumulative dose of 120–140 mg/kg per day has served other dermatological conditions. Peck and colleagues2 pub- us well in the management of acne vulgaris, there is lished the first study of oral 13-cis-retinoic acid (isotretin- emerging evidence that much lower dosages (as low oin) for acne vulgaris in 1979, although initial research had as 5 mg/day) are just as effective but have signifi- started a decade earlier in several Austrian and German cantly fewer adverse effects. Relapse of acne vulgaris dermatology departments. continues to be a problem but we are beginning to Early dose ranging studies3–8 showed there was no dose recognise that this is related less to the cumulative effect in the range of 0.1 to 1.0 mg/kg per day, with both the dose and more to the length of sebaceous gland sup- rate of improvement, and the total clearance of acne, being pression. Other factors important for relapse include the same for 0.1 mg/kg per day as for 1.0 mg/kg per day. a macrocomedonal pattern of acne, smoking and age, However, a number of subsequent studies suggested that both younger (under 14 years) and older (over 25 relapse 1–2 years after a single 16-week course of isotretin- years). After 30 years of use, we now understand why oin was greater in those treated with 0.1 mg/kg per day than isotretinoin is such an effective drug. Not only does it with 1.0 mg/kg per day.9 This was interpreted to indicate clear acne in almost all patients, long-term remission that the best long-term response from isotretinoin was can be achieved in 70–80% of patients with a single obtained if the patient achieved a cumulative dose of 120– course. Important changes in the use of isotretinoin 140 mg/kg.10,11 include using a lower daily dose for a longer period Now 30 years on, it is timely to review what we have of time. New indications continue to emerge, parti- learned over this period. This includes re-evaluating the cularly as a potential treatment for both intrinsic evidence for the daily dose, the duration of treatment, cumulative dose, relapse, non-responsiveness and indica- tions for isotretinoin. THE PATHOPHYSIOLOGY OF ACNE First, though, it is opportune to review our understanding Correspondence: Dr Marius Rademaker, Dermatology Depart- of the pathophysiology of acne. The current model of acne ment, Waikato Hospital, Private Bag, Hamilton, New Zealand. Email: [email protected] Abbreviations: Marius Rademaker, DM. Conflicts of interest: The author was the principal investigator for atRA all-trans retinoic acid a pharmaceutical company (Douglas Pharmaceuticals, Auckland, IL interleukin New Zealand) sponsored trial of very low dose isotretinoin (5 mg/ RAR retinoic acid receptors day) for persistent low-grade adult acne vulgaris. RARE retinoic acid response element Submitted 28 June 2012; accepted 17 July 2012. © 2012 The Author Australasian Journal of Dermatology © 2012 The Australasian College of Dermatologists 2 M Rademaker vulgaris includes a hormonally induced alteration in sebum tin. In other words, there is an initial induction of apoptosis production, abnormal growth and differentiation of epider- and cell cycle arrest, particularly in the sebaceous gland, mal cells leading to hypercornification of the pilosebaceous followed by the skin adopting a wound–healing-like pattern duct, abnormal growth of Propionibacterium acnes and of gene expression, with subsequent repair and remodel- a subsequent auto-immune response. This auto-immune ling.16,17 Clinical experience suggest this may be dose- response appears to be mediated via Toll-like receptor 2 and dependent with reduced scarring at 0.1 mg/kg per day but 4 and the release of pro-inflammatory mediators (inter- hypertrophic scarring at 1–2 mg/kg per day. leukin [IL]-1a, IL-8 and tumor necrosis factor-a).12 These result in neutrophil recruitment, the release of lysosomal enzymes and subsequent disruption of the follicular epithe- DAILY DOSE OF ISOTRETINOIN lium. In addition, there is upregulation of human beta defensin-1 and -2.13 The dose of isotretinoin has been well established at 0.5– 1.0 mg/kg per day for 16–20 weeks to a cumulative dose of 120–140 mg/kg.15 We know this is effective, so why change? RETINOIDS: HOW THEY WORK The main reason is that, while 1 mg/kg per day is as effec- Retinoids, including isotretinoin, can influence cellular tive as 0.1 mg/kg per day in clearing acne, the adverse growth, differentiation, morphogenesis and apoptosis, effects are very much greater. At 1 mg/kg per day, 98% of inhibit tumour promotion and malignant cell growth, exert patients complain of adverse events, while at doses below immuno-modulatory actions and alter cellular cohesive- 0.25 mg/kg per day, half the patients experience no adverse ness.14 They do so through a number of mechanisms, the effects at all, and in those who do, the effects are signifi- most important being their ability to influence gene tran- cantly less severe.18 While the evidence for an association scription. Retinoids exert some of their physiological effects between isotretinoin and psychiatric or gastrointestinal by binding to two distinct families of nuclear receptors: RAR adverse effects remains controversial, a reduction in daily (retinoic acid receptors) and retinoid X receptors, which dose can only be regarded as being of potential benefit. belong to the superfamily of nuclear receptors (that also A further advantage of using a lower dose is the differen- include vitamin D3 receptors, thyroid hormone receptors tial effect on acne scarring. At 1 mg/kg per day there is a and peroxisome proliferator-activated receptors).14 well-established risk of excessive scarring, yet at doses of The direct effects of isotretinoin are mediated through 0.1 mg/kg per day acne scarring is generally much less (see binding to a specific retinoic acid response element (RARE) above). in the promoter region of target genes, whose transcrip- The first published study of isotretinoin for acne used a tion is then activated (this, for example, mediates the dosage range of 1.0–3.3 mg/kg per day.2 However, subse- differentiation-inducing actions of isotretinoin). In contrast, quent dose-ranging studies indicated that there was no dose the anti-proliferative and anti-inflammatory actions of effect in the 0.1–3.0 mg/kg per day range, in that all dosages isotretinoin are believed to be mediated by a negative, indi- cleared acne in equal measure and at the same rate.3–8,19 rect regulatory mechanism. These indirect effects result Plewig and colleagues20 demonstrated that a single from the downregulation of genes that do not contain RARE 10–20-mg daily dose of isotretinoin over 6 months reduced in their promoter region, by antagonising other transcrip- inflammatory lesions by 87–94% and non-inflammatory tion factors, such as activator protein-1 and nuclear factor- lesions by 81–88%. In addition, sebaceous gland size was IL6 through competition for co-activator proteins. In reduced by 35–58%, sebum production by 90–95%, follicu- addition all-trans retinoic acid or tretinoin (atRA) has lar keratinization by 55–70% and Propionibacterium acnes recently been shown to regulate the expression and activa- by 33–73%. Skin surface lipids, however, were reduced tion of Toll-like receptors. by only 6%. Geissler and colleagues21 showed, albeit in It is estimated that isotretinoin affects over 500 genes; 300 patients with seborrhoea, that doses as low as 2.5 mg thrice being upregulated and 200 downregulated, although only weekly were effective in reducing sebum production, imply- 27 of these seem to be mediated via the classic RAR/RARE ing the minimal effective daily dose of isotretinoin is in the pathway. Isotretinoin itself does not bind to retinoic acid order of 2 mg/day, irrespective of bodyweight. receptors, but atRA and 13-cis RA are geometric isomers A recent, as yet unpublished, study (Rademaker and col- and show reversible interconversion. Isotretinoin therefore leagues) of persisting acne vulgaris in adults has shown that acts largely as a pro-drug for atRA, although its metabolites 5 mg/day clears acne very effectively compared to placebo, may also play a significant role.15 with minimal adverse effects.22 Of note, the pattern of gene expression induced by A further disadvantage of higher dosage isotretinoin is the isotretinoin changes over time. Immediately following the well-recognised flare of acne after 3–6 weeks of treatment. commencement of isotretinoin there is upregulation of This may relate to the degree of sebaceous cell apoptosis, tumour suppressor genes, protein processors and genes which can largely be avoided by using doses of below involved in the transfer or binding of ions and small mol- 0.2 mg/kg per day.23,24 The larger the dose of isotretinoin, ecules.16,17 After 8 weeks of treatment there is downregula- the greater the apoptosis of sebocytes and thereby the tion of the genes involved in the metabolism of steroids, greater antigen load to drive the auto-immune response.
Load more

Recommended publications
  • Training Available: in 2012, Lorenzo Kunze, M.E
    2013 Derma-Lo - offers the 2013 Thermo-Lo - offers the reduction of: sun/age spot, milia, reduction of: sun/age spot, milia, telangiectasia / epidermal spider telangiectasia / epidermal spider veins, cherry hemangiomas, veins, cherry hemangiomas and Thermolysis (AC) and Electrolysis Thermolysis (AC) hair removal. (DC) hair removal. Also: active acne, acne scarring, sebaceous hyperplasia, and skin tags. Training Available: In 2012, Lorenzo Kunze, M.E. Includes: Hydro-Lo - treatment IN DENVER ONCE A MONTH developed Chromos, Inc. - which of fine lines and wrinkles, TRAINING AVAILABLE AT in Greek, can be interpreted as enlarged pore reduction, boosts YOUR LOCATION ASK ABOUT “color” or “light” – in essence, the penetration of product into COST without light we have no color. the skin and tightens loose skin. “Dedicated to Excellence” Also: select your choice of (1 of Continuing to provide a professional & positive attitude in the medical 2) LED’s – both are non invasive and aesthetic field. hand-held light probes: BLUE for CHROMOS, Inc. the treatment of acne or Lorenzo Kunze, M.E. Chromos strives to be a guiding INFRARED to increase collagen [email protected] “light” that assists medical and and elastin, Rosacea, increased www.DermaLo.com aesthetic professionals in finding healing properties, minor muscle www.Thermo-Lo.com and pursuing proper education and moderate joint pain. 888-499-8991 / 303-994-7236 and accurate knowledge. Lorenzo Kunze, M.E. Lorenzo is a true visionary - 40 years in the medical and aesthetic field Medical Electrologist / medical educator 1st non-medical professional to provide electrolysis treatments in an OR Treated over 20,000 patients - last 16 years 1st in the U.S.
    [Show full text]
  • Dermatology DDX Deck, 2Nd Edition 65
    63. Herpes simplex (cold sores, fever blisters) PREMALIGNANT AND MALIGNANT NON- 64. Varicella (chicken pox) MELANOMA SKIN TUMORS Dermatology DDX Deck, 2nd Edition 65. Herpes zoster (shingles) 126. Basal cell carcinoma 66. Hand, foot, and mouth disease 127. Actinic keratosis TOPICAL THERAPY 128. Squamous cell carcinoma 1. Basic principles of treatment FUNGAL INFECTIONS 129. Bowen disease 2. Topical corticosteroids 67. Candidiasis (moniliasis) 130. Leukoplakia 68. Candidal balanitis 131. Cutaneous T-cell lymphoma ECZEMA 69. Candidiasis (diaper dermatitis) 132. Paget disease of the breast 3. Acute eczematous inflammation 70. Candidiasis of large skin folds (candidal 133. Extramammary Paget disease 4. Rhus dermatitis (poison ivy, poison oak, intertrigo) 134. Cutaneous metastasis poison sumac) 71. Tinea versicolor 5. Subacute eczematous inflammation 72. Tinea of the nails NEVI AND MALIGNANT MELANOMA 6. Chronic eczematous inflammation 73. Angular cheilitis 135. Nevi, melanocytic nevi, moles 7. Lichen simplex chronicus 74. Cutaneous fungal infections (tinea) 136. Atypical mole syndrome (dysplastic nevus 8. Hand eczema 75. Tinea of the foot syndrome) 9. Asteatotic eczema 76. Tinea of the groin 137. Malignant melanoma, lentigo maligna 10. Chapped, fissured feet 77. Tinea of the body 138. Melanoma mimics 11. Allergic contact dermatitis 78. Tinea of the hand 139. Congenital melanocytic nevi 12. Irritant contact dermatitis 79. Tinea incognito 13. Fingertip eczema 80. Tinea of the scalp VASCULAR TUMORS AND MALFORMATIONS 14. Keratolysis exfoliativa 81. Tinea of the beard 140. Hemangiomas of infancy 15. Nummular eczema 141. Vascular malformations 16. Pompholyx EXANTHEMS AND DRUG REACTIONS 142. Cherry angioma 17. Prurigo nodularis 82. Non-specific viral rash 143. Angiokeratoma 18. Stasis dermatitis 83.
    [Show full text]
  • Rosacea: an Update
    REVIEW JONELLE K. MCDONNELL, MD KENNETH J. TOMECKI, MD Department of Dermatology, Cleveland Clinic Department of Dermatology, Cleveland Clinic Rosacea: An update • ABSTRACT | >1 OSACEA is a chronic and recurrent LAM inflammatory skin disease characterized Rosacea is a common inflammatory skin disease affecting by erythema, papules, pustules, telangiectasia, the central face of adults. Its etiology is unknown. Early and occasionally sebaceous hyperplasia, which diagnosis and appropriate treatment, usually with topical or primarily affects the central face. The disease systemic antibiotics or both, minimizes symptoms and helps evolves in stages and affects middle-aged to prevent complications. adults. Early diagnosis and thoughtful manage- ment help to control the disease and to mini- • KEY POINTS mize the patient's discomfort and emotional distress. Historically, rosacea has been a mis- Rosacea has a spectrum of cutaneous clinical findings: understood disorder, often attributed to alco- facial erythema, papules, pustules, telangiectasia, and holism and acne.1 rhinophyma. • INCIDENCE Common triggers are sunlight, stress, exposure to extreme Rosacea is a common and chronic disease that heat or cold, alcohol, hot beverages, and spicy foods. affects approximately 13 million Americans, or about 1 in 20 people. Because rosacea fre- Rosacea can resemble other diseases, including acne, quently affects people of northern European seborrheic dermatitis, systemic lupus erythematosus, and heritage, it is often called the "curse of the sarcoidosis. Celts."2 In contrast, it is rarely seen in dark- skinned individuals.3 In most patients, the Ocular involvement occurs in more than 50% of patients onset occurs between the ages of 30 and 50. with rosacea. The early stages affect women more often than men at a ratio of 3 to 1, but men more often Oral tetracycline and topical metronidazole are the develop disfiguring rhinophyma.
    [Show full text]
  • A Case of Steatocystoma Simplex Involving the Scalp
    230 A Case of Steatocystoma Simplex Involving the Scalp Dong Nyeok Hyun, M.D., Jong Hoon Won, M.D., Joon Soo Park, M.D., Hyun Chung, M.D. Department of Dermatology, School of Medicine, Catholic University of Daegu, Daegu, Korea Steatocystoma is a benign adnexal tumor originating from the pilosebaceous duct junction which can be classified into two groups (steatocystoma simplex and steatocystoma multiplex). Steatocystoma simplex, which presents as a solitary lesion, is very rare. Steatocystoma simplex occurs most commonly on the face and the case reported herein involving the scalp is extremely rare. A 49-year-old man presented for evaluation and treatment of a solitary papule on the right parietal scalp which had persisted for a period of 1 year. The histopathologic examination revealed a thin-walled cyst consisting of stratified squamous epithelium with hyaline cuticle that lacked a stratum granulosum. Based on clinical and histologic findings, we diagnosed this case as steatocystoma simplex of the scalp and report this rare case. (Ann Dermatol (Seoul) 20(4) 230∼232, 2008) Key Words: Scalp, Steatocystoma simplex INTRODUCTION CASE REPORT Steatocystoma simplex, first described as a dis- A 49-year-old man presented to our outpatient tinct entity by Brownstein1 in 1982, is an extremely clinic with an asymptomatic papule on the right rare benign adnexal tumor. The individual lesion of parietal scalp which had been present for about 1 steatocystoma simplex is usually identical with that year. The lesion had slowly enlarged a few months of steatocystoma multiplex, both clinically and ago. The physical examination revealed a skin- histologically, but is characterized by solitary, non- colored, deep-seated, soft cystic mass on his right heritable growth in adulthood1.
    [Show full text]
  • Pathogenesis of Rosacea Anetta E
    REVIEW Pathogenesis of Rosacea Anetta E. Reszko, MD, PhD; Richard D. Granstein, MD Rosacea is a chronic, common skin disorder whose pathogenesis is incompletely understood. An inter- play of multiple factors, including genetic predisposition and environmental, neurogenic, and microbial factors, may be involved in the disease process. Rosacea subtypes, identified in the recently published standard classification system by the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea, may in fact represent different disease processes, and identifying subtypes may allow investigators to pursue more precisely focused studies. New developments in molecular biology and genetics hold promise for elucidating the interplay of the multiple factors involved in the pathogen- esis of rosacea, as well as providing the bases for potential new therapies. osacea is a common, chronic skin disorder and secondary features needed for the clinical diagnosis primarily affecting the central and con- of rosacea. Primary features include flushing (transient vex areas of COSthe face. The nose, cheeks, DERM erythema), persistent erythema, papules and pustules, chin, forehead, and glabella are the most and telangiectasias. Secondary features include burn- frequently affected sites. Less commonly ing and stinging, skin dryness, plaque formation, dry affectedR sites include the infraorbital, submental, and ret- appearance, edema, ocular symptoms, extrafacial mani- roauricular areas, the V-shaped area of the chest, and the festations, and phymatous changes. One or more of the neck, the back, and theDo scalp. Notprimary Copy features is needed for diagnosis.1 The disease has a variety of clinical manifestations, Several authors have theorized that rosacea progresses including flushing, persistent erythema, telangiecta- from one stage to another.2-4 However, recent data, sias, papules, pustules, and tissue and sebaceous gland including data on therapeutic modalities of various sub- hyperplasia.
    [Show full text]
  • Cancer Immunoprevention: a Case Report Raising the Possibility of “Immuno-Interception” Jessica G
    CANCER PREVENTION RESEARCH | RESEARCH BRIEF Cancer Immunoprevention: A Case Report Raising the Possibility of “Immuno-interception” Jessica G. Mancuso1, William D. Foulkes1,2,3, and Michael N. Pollak1,2 ABSTRACT ◥ Immune checkpoint blockade therapy provides substan- or neoplastic lesions over a period of 19 years (mean tial benefits for subsets of patients with advanced cancer, 7.5 neoplasms/year, range 2–26) prior to receiving but its utility for cancer prevention is unknown. Lynch pembrolizumab immunotherapy as part of multi- syndrome (MIM 120435) is characterized by defective modality treatment for invasive bladder cancer. He not DNA mismatch repair and predisposition to multiple only had a complete response of the bladder cancer, but cancers. A variant of Lynch syndrome, Muir–Torre also was noted to have an absence of new cancers during a syndrome (MIM 158320), is characterized by frequent 22-month follow-up period. This case adds to the rationale gastrointestinal tumors and hyperplastic or neoplastic skin for exploring the utility of immune checkpoint blockade tumors. We report the case of a man with Muir–Torre forcancerprevention,particularlyforpatientswithDNA syndrome who had 136 cutaneous or visceral hyperplastic repair deficits. Introduction There is an obvious clinical need to reduce cancer incidence in patients with DNA repair deficits, and prophylactic surgery The clinically demonstrated utility of antiviral vaccines to is commonly employed. Clinical trials designed to evaluate reduce risk of virally initiated cancers represents a major strategies to reduce cancer incidence are challenging: in popu- success in cancer immunoprevention. There is interest in the lations where baseline risk is low, a large number of subjects and possibility that immunoprevention may also be useful where long follow-up periods are required.
    [Show full text]
  • Price Sheet 01-01-21
    SERVICES & PRICING DERM CASH PRICES – FOR COSMETIC PROCEDURES Sebaceous Hyperplasia (Any #) . $150.00 Milia (Any #) . $100.00 Seborrheic Keratoses (Full Back Greater than 40) . $500.00 Seborrheic Keratoses (Half Back) . $250.00 Seborrheic Keratosis (Face) . $200.00 Lentigo (1-5 with TCA) . $150.00 Cherry Angiomas (Per Region) . $150.00 Benign Nevi (Per Spot) . $150.00 Skin Tags (1-15) . $100.00 Skin Tags (16 -25) . $150.00 Skin Tags (26 or more) . $250.00 AEROLASE CONDITION QTY FREQUENCY COST PER QTY. LENTIGO (1) 3 – 4 EVERY 3 – 4 WEEKS $50.00 LENTIGO (2-5) 3 – 4 EVERY 3 – 4 WEEKS $150.00 LENTIGOS (FULL FACE) 3 – 4 EVERY 3 – 4 WEEKS $250.00 FRECKLING/PIH 3 – 4 EVERY 3 – 4 WEEKS $275.00 MELASMA 4+ EVERY 3 – 4 WEEKS $250.00 ANGIOMA (1) 2 – 3 EVERY 3 – 4 WEEKS $50.00 ANGIOMAS (2-5) 2 – 3 EVERY 3 – 4 WEEKS $150.00 ANGIOMAS (FULL FACE) 2 – 3 EVERY 3 – 4 WEEKS $250.00 TELANGECTASIAS (FACE) 2 – 3 EVERY 3 – 4 WEEKS $250.00 SPIDER VEINS (LEGS) 3 – 4 EVERY 3 – 4 WEEKS $500.00 POIKILODERMA 3 – 4 EVERY 3 – 4 WEEKS $300.00-400.00 SCARS (1-5) 4 EVERY 3 – 4 WEEKS $150.00 STRETCH MARKS 4 EVERY 3 – 4 WEEKS $250.00 FACIAL REJUVENATION 4 EVERY 3 – 4 WEEKS $400.00 PSEUDOFOLLICULITIS BARBAE 3 – 4 EVERY 2 – 3 WEEKS $150.00 AMOUNT BILLED ACNE AND/OR ROSACEA *INSURANCE 4+ EVERY 2 WEEKS TO INSURANCE $180.00 IF PAID IN FULL ACNE AND/OR ROSACEA * CASH 4+ EVERY 1 –2 WEEKS AT TIME OF SERVICE $126.00 WARTS *INSURANCE 2+ EVERY 2 – 3 WEEKS --- WARTS * CASH 2+ EVERY 2 – 3 WEEKS $100.00 PSORIASIS $ (SMALL AREA) 6+ 1 WEEK $100.00 PSORIASIS - INSURANCE (PA REQ.) 6+ EVERY 2 WEEKS --- WOUND HEALING 3 – 6 1 – 2 TIMES A WEEK $150.00 TOENAIL FUNGUS (PER TOE) 1 – 4 EVERY 4 WEEKS $100.00 *Cash price for patients without insurance.
    [Show full text]
  • The Treatment of Giant Rhinophyma - Case Report (1) (2) D
    Current Health Sciences Journal Vol. 38, No. 2, 2012 April June Case Report The treatment of giant rhinophyma - Case Report (1) (2) D. POPA , GEORGETA OSMAN , H. (1) (3) (1) PARVANESCU ,RALUCA CIUREA , M. CIUREA (1) Department of Plastic and Reconstructive Surgery, University of Medicine and Pharmacy of Craiova; (2) Departament of E.N.T., Emergency University Hospital, Craiova, (3) Department of Pathology, University of Medicine and Pharmacy of Craiova ABSTRACT The aim of the article is to present an update on the pathophysiology, clinical features and treatment of rhinophyma. A 56 years old patient, living in urban area, presented with a giant rhinophyma which caused him not only upper airways obstruction and difficulty in eating, but also aesthetic and psycho-social disadvantages.The treatment of the patient was a surgical intervention consisting in removal of the nasal tumor and split-thickness skin grafting of the defect. The aesthetic result after surgical intervention was very good, there were no postoperative complications or recurrences.Rhinophyma represents the most advanced form of acne rosacea. The diagnosis is easy to establish based on the clinical features of the disease. In advanced forms of rhinophyma, when the tumor is giant, the main method of treatment is surgery. KEY WORDS rhinophyma , sebaceous hyperplasia, nasal tumor Introduction Rhinophyma, exuberant hypertrophic acne, with tumoral aspect of the skin of nasal pyramid is characterized by large, bulbous, erythematous appearance of the nose. It can also cause upper airways obstruction and difficulty in eating. The word rhinophyma is derived from the Greek word “rhis” meaning nose and “phyma” meaning growth .This disease mainly occurs in men after 50 years.
    [Show full text]
  • Treatment of Aged Skin with Oral 13-Cis-Retinoic Acid
    Europaisches Patentamt European Patent Office © Publication number: 0 357 646 B1 Office europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 22.03.95 © Int. CI.6: A61 K 31/07, A61 K 31/20 © Application number: 88903704.0 @ Date of filing: 05.04.88 © International application number: PCT/US88/01103 © International publication number: WO 88/07857 (20.10.88 88/23) The file contains technical information submitted after the application was filed and not included in this specification © TREATMENT OF AGED SKIN WITH ORAL 13-CIS-RETINOIC ACID. ® Priority: 06.04.87 US 35544 © Proprietor: DALTEX MEDICAL SCIENCES, INC. 50 Kulick Road @ Date of publication of application: Second Floor 14.03.90 Bulletin 90/11 Fairfield, NJ 07006 (US) © Publication of the grant of the patent: @ Inventor: PLEWIG, Gerd 22.03.95 Bulletin 95/12 Cecilienallee 38 D-4000 Dusseldorf 30 (DE) © Designated Contracting States: Inventor: KLIGMAN, Albert, M. AT BE CH DE FR GB IT LI LU NL SE 637 Pine Street Philadelphia, PA 19106 (US) © References cited: GB-A- 1 335 867 Representative: Koepsell, Helmut, Dipl. Ing. Retinoids, ED.; C.E. ORFANOS et al., pub- Mittelstrasse 7 lished 29 July 1981, pp. 219-223, 232-235, see D-50672 Koln (DE) entire document 00 CO CO m Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art.
    [Show full text]
  • Photodynamic Therapy and Skin Appendage Disorders: a Review
    Review Article Skin Appendage Disord 2016;2:166–176 Received: September 28, 2016 DOI: 10.1159/000453273 Accepted: November 7, 2016 Published online: December 8, 2016 Photodynamic Therapy and Skin Appendage Disorders: A Review Matteo Megna Gabriella Fabbrocini Claudio Marasca Giuseppe Monfrecola Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples , Italy Key Words Introduction Photodynamic therapy · Hidradenitis suppurativa · Acne · Sebaceous hyperplasia · Onychomycosis Photodynamic therapy (PDT) is a noninvasive treat- ment that utilizes light treatment along with an applica- tion of a photosensitizing agent in the presence of mo- Abstract lecular oxygen [1–3] . The scientific basis of PDT has Photodynamic therapy (PDT) is a noninvasive treatment that been recognized since 1900; Oscar Raab and Herman utilizes light treatment along with application of a photosen- von Tappeiner were first to report the concept of cell sitizing agent. In dermatology, PDT is commonly used and death being induced by the interaction of light and chem- approved for the treatment of oncological conditions such icals [4–5] . Shortly afterwards, von Tappeiner and Je- as actinic keratosis, Bowen disease and superficial basal cell sionek [6] performed the first medical application in der- carcinoma. In the last 2 decades however, PDT has also been matology, using a combination of topical eosin and white used for the treatment of several nonneoplastic dermato- light to treat skin tumors. Nevertheless, numerous
    [Show full text]
  • A 5 Year Histopathological Study of Skin Adnexal Tumors at a Tertiary Care Hospital
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 14, Issue 4 Ver. VII (Apr. 2015), PP 01-05 www.iosrjournals.org A 5 Year Histopathological Study of Skin Adnexal Tumors at a Tertiary Care Hospital Dr.Vani.D1, Dr.Ashwini.N.S2, Dr.Sandhya.M3, Dr.T.R.Dayananda4, Dr.Bharathi.M5 1,2,3,5, Department of Pathology, Mysore Medical College & Research Institute, Mysore, India 4, Department of Dermatology, BGS Apollo Hospital, Mysore, India Abstract: Introduction: Skin adnexal neoplasms are uncommon and are daunting diagnostic problems in view of the wide spectrum of lesions and their variants. Benign adnexal neoplasms are more common than malignant lesions. Aim: To study histopathology of skin adnexal neoplasms and to correlate with the clinical profile. Methodology: 51cases with a diagnosis of skin adnexal neoplasm over a 5 year period reported in the Department of Pathology, Mysore Medical College & Research Institute were included in the study. Histopathological examination was done on Haematoxylin& Eosin stained slides and corroborated with special stains wherever required. Results: Skin adnexal tumors were most common in the age group of 40 to 49 years (21.56%, 11/51). Male to female ratio was 1:1.68. The head and neck region was the most common site affected (64.70%, 33/51) with 39.21% (20/51) caseslocated on the face. 74.50% (38/51) cases were benign and 25.49% (13/51) cases were malignant. The sweat gland tumors formed the largest group involving 43.13% (22/51) cases followed by the hair follicle tumors 37.25% (19/51) followed by sebaceous gland tumors 19.60% (10/51).
    [Show full text]
  • Buffalo Medical Group, P.C. Robert E
    Buffalo Medical Group, P.C. Robert E. Kalb, M.D. Phone: (716) 630-1102 Fax: (716) 633-6507 Department of Dermatology 325 Essjay Road Williamsville, New York 14221 2 FOOT- 1 HAND SYNDROME 2 foot - 1 hand syndrome is a superficial infection of the skin caused by the common athlete's foot fungus. It is quite common for people to have a minor amount of an athlete's foot condition. This would appear as slight scaling and/or itching between the toes. In addition, patients may have thickened toenails as part of the athlete's foot condition. Again the problem on the feet is very common and often patients are not even aware of it. In some patients, however, the athlete's foot fungus can spread to another area of the body. For some strange and unknown reason, it seems to affect only one hand. That is why the condition is called 2 foot - 1 hand syndrome. It is not clear why the problem develops in only one hand or why the right or left is involved in some patients. Fortunately there is very effective treatment to control this minor skin problem. If the problem with the superficial fungus infection is confined to the skin, then a short course of treatment with an oral antibiotic is all that is required. This antibiotic is very safe and normally clears the skin up fairly rapidly. It is often used with a topical cream to speed the healing process. If, however, the fingernails of the affected hand are also involved then a more prolonged course of the antibiotic will be necessary.
    [Show full text]